Sociodemographic Characteristics Associated with PCSK9 Inhibitor Use in Individuals with Possible Familial Hypercholesterolemia in Alberta: A Cohort Study
{{output}}
Background: Proprotein convertase subtilisin/kinase type 9 inhibitors (PCSK9is) significantly lower low-density lipoprotein cholesterol (LDL-c) level and improve cardiovascular outcomes, but they remain underutilized, potentially... ...
